The Paradigm Shift in Drug R&D

The Paradigm Shift in Drug R&D

By Pharma Tech Outlook | Monday, September 10, 2018

Today, drug research and development (R&D) department of pharmaceutical firms incorporates many operations such as drug development and production, synthesis of specialized cells or molecules, and various clinical trials of drugs. Nevertheless, this was not the case a few years ago. The entire process of development and manufacturing of a new drug or medical marvel to arrive in the healthcare market would require approximately 10 to 15 years. However, the pharma industry is currently employing the benefits of biotechnology in its R&D department to shorten this gap. A paradigm shift in the drug development began with the advent of biotechnology, which led the pharma industry in the direction of developing cell-engineered products and gene and cell therapy.

The need for an enhanced manufacturing technology appeared with the rapid growth of the clinical study of gene and cell therapy. Developing a specialized pharma product has given rise to a robust and well-characterized production method that ensures a successful clinical trial phase and reliable commercialization. With the objective to deploy an advanced gene therapy in the healthcare space, the pharma industry is working on a robust gene therapy development pipeline based on previously collected data. In response to these needs, multiple laboratories and pharma companies have developed various advanced technologies to aid them in gene therapy clinical trials and its marketing in future. Furthermore, the pharma companies are also focusing on scalability and customization of genes and cell manufacturing technology for a better prospect for their clinical development and commercialization.

The paradigm shift in the drug R&D of pharma companies has also put forth the benefits of collaboration between the scientists who indulge in drug discovery and the manufacturers who center their work on the industrialization of drugs. The new approach towards manufacturing and development of healthcare products has shown that both of the above views were imminent to the pharma industry. The sector has begun to understand that R&D of medical products requires the balance between making it efficient and producing it in a significant amount. With this, the pharma companies are following a step-by-step procedure to deliver the expected clinical results while also making sure that the drugs are marketed fittingly.

Weekly Brief

New Editions